• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
PHT 415 student Handout 3031
PHT 415 student Handout 3031

... a. Assuming no loading dose, how long after the start of the IV infusion would it take to reach 95% of the C SS? b. What is the proper loading dose for this antibiotic? c. What is the proper infusion rate for this drug? d. What is the amount of the drug in the body at steady-state? e. What is the to ...
Herbal drugs and drug interactions
Herbal drugs and drug interactions

... estimates of use, reaching 61 to 71 % (1,11). We could not find a similar survey made in Turkey. Besides, in Turkey and in many other cuntries (especially in developing countries), it is common practice to use folk medicines or products prepared unofficially by people specializd in the field (called ...
Accutane: Has Drug Regulation in the United States Reached Its
Accutane: Has Drug Regulation in the United States Reached Its

... of the drug, and to discover less common side effects and other information. Upon completion, the sponsor files a "New Drug Application" ("NDA") with the FDA. Final approval of the drug will depend on whether the manufacturer has proven that the drug is safe' and effective, and the development of sa ...
Sample Chapter
Sample Chapter

... Birth defects, together with deformations and chromosomal abnormalities, are a leading cause of neonatal and postneonatal deaths and carry a high social and economic impact. According to the most recent analysis in 1992, the estimated lifetime cost for all infants with one or more of the 18 most c ...
IN SITU IMPLANTS FOR PARENTERAL ADMINISTRATION    Research Article
IN SITU IMPLANTS FOR PARENTERAL ADMINISTRATION    Research Article

... again  to  remove  the  polymer  from  the  body  after  once  the  formulation  is  injected  which  is  very  common  with  conventional  implants.  However  burst  release  is  a  common  problem  which  still  remains  to  be  solved,  it  can  be  reduced  by  using  suitable  hydrophobic excip ...
C  O L
C O L

... Small intestinal transit 3-4 hours Colon transit ...
- Journal of SOPI
- Journal of SOPI

... There are large number of drug trial going on world wide to observe the effect of a particular drug or a molecule. However, the scenario has changed drastically in last 20 years. What it was with the western/ developed world is now shifting over to developing world. India is set to grab clinical tri ...
The Biochemistry of Drug Metabolism
The Biochemistry of Drug Metabolism

... Since then, many books have appeared, most of them being edited ones offering expertly written reviews; some such books are listed in the References [7 – 20]. Other books were written by one or two authors, their import and tone being more unitarian and didactic (e.g., [21 – 28]). The present Work f ...
Drug-related morbidity and mortality: Pharmacoepidemiological aspects Anna K. Jönsson
Drug-related morbidity and mortality: Pharmacoepidemiological aspects Anna K. Jönsson

... the patient as well as for society. Suspected ADRs have been reported to occur in about 214% of hospitalised patients. In about 5% of deceased hospitalised patients suspected ADRs may have caused or contributed to the fatal outcome. When a pharmaceutical drug is approved for marketing, the drug has ...
Research article DOPING AND PERFORMANCE ENHANCING
Research article DOPING AND PERFORMANCE ENHANCING

... used were anabolic steroids in 60.5%, l-carnitene in 12.7%, erythropoietin in 5.4%, Na-bicarbonate in 11.3% and creatinine in 14.1% of 71 cases. Over a quarter percent (28.6%) of drug offenders reported taking them in regular intervals. In the present study, 41.3% of the cases reported that their fr ...
The role of the quantity in the prosecution of drug offences
The role of the quantity in the prosecution of drug offences

... In this way, if it is not easy to prove the intention of the offender, the Convention effectively leaves the qualification of the offence to the Parties. The consequences of the distinction are that many of the obligations under international law set out in the 1988 Convention do not apply to the of ...
INTERNATIONAL PHARMACy jOuRNAL
INTERNATIONAL PHARMACy jOuRNAL

... tionizing therapeutic options for many previous untreated or poorly treated diseases. Monoclonal antibodies have been used alone, coupled with small-molecule cargo, or as derivatives. Like nucleic acid derived compounds, namely ­oligonucleotides, siRNA and miRNA, they are at the same time potential ...
Paul G. King Consulting
Paul G. King Consulting

... Based on the preceding, it is recommended that the guidance should be modified to require the appropriate toxicity studies on the impurity fractions derived from the “mother liquor” of the final purification of the active pharmaceutical ingredient. Then, if no evidence of significant acute or chroni ...
Full Text
Full Text

... drug manufacturers can make in comparison with manufacturers of foods, cosmetics, or dietary supplements. While manufacturers of articles not classified as prescription drugs must still comply with the advertising standards of the Lanham Act, they have much more flexibility in terms of the uses they ...
International Journal Of Pharma Professional`s Research RECENT
International Journal Of Pharma Professional`s Research RECENT

... can be treated by this approach. This is observed by microneedles with applied formulation; (b) Solid microneedles analyzing potency, safety and tolerability parameters of Microneedles are tiny and very sleek devices that are the rivastigmine patch which was compared with placebo manufactured by the ...
Drug Development Pipeline
Drug Development Pipeline

... $1.25 billion per NME; in 1995 that number was $317 million+ * Health care costs main cause of bankruptcy, study finds, The New Standard, at ...
Slide 1
Slide 1

... Thin film drug delivery is a process of delivering drugs to the systemic circulation via a thin film that dissolves when in contact with liquid, often referred to as a dissolving film or strip. thin film strips are typically designed for oral administran, with the user placing the strip on or under ...
Re: Draft Guidance "Pharmacy Compounding of Human
Re: Draft Guidance "Pharmacy Compounding of Human

... provided by FDA. PCCA believes that a rigid take-it-or-leave-it approach would implicate thorny issues of federalism. It will also force pharmacies to determine, because of some arbitrary number, which patients should receive their compounded medication and which should not. Doing so will negatively ...
Sample pages 1 PDF
Sample pages 1 PDF

... absorption, distribution, metabolism, and excretion; that is why, average doses will produce average responses, and for many drugs with wide safety margins, this is sufficient. However, some drugs do not have wide safety margins and knowledge of clinical pharmacokinetics in the individual is vital t ...
Transnasal Drug Delivery
Transnasal Drug Delivery

... Kurt L Berens is a Senior Scientist in Programme Development at Mystic Pharmaceuticals and has been involved in pharmaceutical and medical device research and development for more than 25 years. He was previously Vice President of Product Development at CytoGenix, Inc., and additional industry exper ...
Kidney-Specific Drug Delivery: Review of Opportunities
Kidney-Specific Drug Delivery: Review of Opportunities

... soluble or to the particle type carriers. The main backbone of these carriers is based on diversity of polymers such as dextran, ficoll, sepharose, or PLL. Nowadays, poly(D,L-lactic-co-glycolic-acid) (PLGA) microspheres have been widely studied to gain a wide acceptance for application as nanopartic ...
For more information on accessing electronic
For more information on accessing electronic

... Cancer nanotherapeutics are progressing at a steady rate; research and development in the field has experienced an exponential growth since early 2000's. The path to the commercialization of oncology drugs is long and carries significant risk; however, there is considerable excitement that nanoparti ...
Orally disintegrating tablets - Journal of Applied Pharmaceutical
Orally disintegrating tablets - Journal of Applied Pharmaceutical

... regarded as the safest, most convenient and most economical method of drug delivery having the highest patient compliance. Formulation of a convenient dosage form for oral administration, by considering swallowing difficulty especially in case of geriatric and pediatric patient leads to poor patient ...
SUSTAINED RELEASE AEROSOL FOR PULMONARY DRUG DELIVERY SYSTEM: A REVIEW
SUSTAINED RELEASE AEROSOL FOR PULMONARY DRUG DELIVERY SYSTEM: A REVIEW

... pulmonary absorption. Lung has thin barrier with large surface area, higher systemic bioavailability, drugs are better absorbed. Therefore faster absorption occurred in lung after inhalation, challenge is the formulation should stay in local site of the lung and release the drug for the prolonged pe ...
FORMULATION AND EVALUATION OF PULSATILE TABLET IN CAPSULE DEVICE Research Article
FORMULATION AND EVALUATION OF PULSATILE TABLET IN CAPSULE DEVICE Research Article

... Development of suitable chronotherapeutic oral dosage forms can be achieved using delayed and/or pulsatile technologies. A pulsatile release is characterized by proportioning drug concentration throughout 24-hour period (circadian rhythm) in synchrony with biological rhythm determinants of disease h ...
< 1 ... 25 26 27 28 29 30 31 32 33 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report